Skip to main content

Advertisement

Table 1 Key baseline patient demographics and characteristics

From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Characteristic Overall (N = 130)a Patients with best response of SD (n = 32)
Age, median (range), y 61 (20–83) 61.5 (24–79)
ECOG performance statusb
 0 46 (35) 10 (31)
 1 66 (51) 17 (53)
 2 17 (13) 5 (16)
International Prognostic Index, n (%)
 <2 31 (24) 7 (22)
 ≥2 99 (76) 25 (78)
PTCL subtype based on central review, n (%)
 PTCL-NOS 69 (53) 16 (50)
 AITL 27 (21) 8 (25)
 ALK-1-negative ALCL 21 (16) 5 (16)
 Other 13 (10)c 3 (9)d
Stage III/IV at diagnosis, n (%) 91 (70) 20 (63)
Number of prior therapies, n (%)
 1 38 (29) 13 (41)
 2 44 (34) 11 (34)
 3 19 (15) 3 (9)
 4 15 (12) 4 (13)
 >4 14 (11) 1 (3)
Type of prior therapy, n (%)
 Chemotherapy 129 (99) 31 (97)
 Monoclonal antibody therapy 20 (15) 3 (9)
 Other immunotherapy 14 (11) 1 (3)
 Radiation 31 (24) 8 (25)
 ASCT 21 (16) 3 (9)
Refractory to most recent therapy, n (%) 49 (38) 8 (25)
  1. ASCT autologous stem cell transplant
  2. a PTCL histologically confirmed by central pathology review
  3. b One patient in the overall population had missing ECOG performance status at baseline
  4. cIncludes enteropathy-associated TCL (6), subcutaneous panniculitis-type TCL (3), ALK-1-positive ALCL (1), cutaneous γδ TCL (1), extranodal NK/TCL nasal type (1), and transformed mycosis fungoides (1)
  5. dIncludes enteropathy-type TCL (1), subcutaneous panniculitis-like TCL (1), and cutaneous γδ TCL (1)